Drug Profile
PL 2258
Alternative Names: PL2258; PL2258-Merck; PL2258BLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co; Piramal Healthcare
- Developer Piramal Enterprises
- Class Antineoplastics; Small molecules
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in India (PO)
- 01 Sep 2014 Piramal suspends phase I trial in Solid tumours (Late-stage disease, Second-line or greater therapy) in India (NCT01779336)
- 01 Dec 2012 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line or greater therapy) in India (PO)